Applied Integrin Sciences, Inc. Announces Exceptional Results In Ovarian Cancer Study
NEW YORK, Sept. 20, 2013 /PRNewswire-iReach/ -- Applied Integrin Sciences, Inc. announced today that its first cancer therapeutic drug candidate eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen. Funded by the National Cancer Institute through the company's first NCI grant awarded December last year, its lead candidate drug Vicrostatin was combined with a drug-eluting gel and applied into the peritoneum for sustained release of the drug directly to ovarian cancer metastatic tumors.
"The results our scientists achieved are exceptional", said Thomas C. Chen, MD, Ph.D., the company's Chief Medical Officer, "and suggest an equivalent human treatment for ovarian cancer patients is feasible. The implications for this treatment are equally compelling as 75% of women first diagnosed with ovarian cancer have stage III or stage IV metastatic disease and 80% of those women fail to survive longer than 20 months post diagnosis. This approach is early but if we are able to achieve comparable results in human clinical trials with women suffering from ovarian cancer this treatment could considerably change the current standard of care."
The company's two drug candidates previously demonstrated substantial reduced tumor growth and progression in pre-clinical testing against six aggressive cancers: triple negative breast cancer; primary prostate cancer; prostate bone metastasis; ovarian cancer; melanoma; and glioblastoma. Both drug candidates, Vicrostatin and ADM-01, are recombinant proteins discovered by the company's founding scientists at the University of Southern California's Keck School of Medicine and Norris Comprehensive Cancer Center. Each uniquely targets specific cell surface receptors that are activated only in actively growing cancer cells and when metastatic cells and cells producing new tumor vasculature are actively motile. These cancer growth and progression processes are necessary for cancers to seed new metastatic tumors throughout the body and to produce the blood vasculature that is required for tumors to grow and cause death.
The cancer fighting mechanisms of the company's two drug candidates are very unique and suggest better efficacy, improved safety, and longer sustained therapeutic effects than current cancer drugs. The company plans to complete pre-clinical development of its lead candidate and file an Investigational New Drug application with the FDA to begin human clinical trials with funds it receives from its next round of financing.
About Applied Integrin Sciences
Applied Integrin Sciences is a pre-clinical stage biopharmaceutical company committed to discover, develop, and commercialize novel drug therapies and treatments for cancer that reduce tumor growth and progression and improve patient survival and quality of life. The Company's Founding Scientists discovered, developed and patented a drug discovery platform to produce novel integrin-modulating recombinant protein drugs that reduce tumor growth and progression in primary tumors, newly growing vasculature, and metastatic foci. The company recruited an outstanding team of exceptional industry-experienced drug development and business executives to lead the company and its drug development program. The company is evaluating a novel treatment for ovarian cancer, an orphan indication recently funded by the National Cancer Institute, as its first indication. For additional information about the company, please visit www.integrins.com.
Source: Applied Integrin Sciences, Inc.
Olmstead Williams Communications, Inc.
Media Contact: Public Relations, Applied Integrin Sciences, Inc., (805) 715-4166, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Applied Integrin Sciences, Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.